Literature DB >> 23517473

Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates.

Lluis Samaranch1, Ernesto A Salegio, Waldy San Sebastian, Adrian P Kells, John R Bringas, John Forsayeth, Krystof S Bankiewicz.   

Abstract

The present study builds on previous work showing that infusion of adeno-associated virus type 9 (AAV9) into the cisterna magna (CM) of nonhuman primates resulted in widespread transduction throughout cortex and spinal cord. Transduction efficiency was severely limited, however, by the presence of circulating anti-AAV antibodies. Accordingly, we compared AAV9 to a related serotype, AAV7, which has a high capsid homology. CM infusion of either AAV7 or AAV9 directed high level of cell transduction with similar patterns of distribution throughout brain cortex and along the spinal cord. Dorsal root ganglia and corticospinal tracts were also transduced. Both astrocytes and neurons were transduced. Interestingly, little transduction was observed in peripheral organs. Our results indicate that intrathecal delivery of either AAV7 or AAV9 directs a robust and widespread cellular transduction in the central nervous system and other peripheral neural structures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23517473      PMCID: PMC3655626          DOI: 10.1089/hum.2013.005

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  19 in total

1.  Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain.

Authors:  Benjamin Storek; Matthias Reinhardt; Cheng Wang; William G M Janssen; Nina M Harder; Michaela S Banck; John H Morrison; Andreas S Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

2.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

Review 3.  Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.

Authors:  J Fraser Wright; Guang Qu; Chunlin Tang; Jurg M Sommer
Journal:  Curr Opin Drug Discov Devel       Date:  2003-03

4.  The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain.

Authors:  Piotr Hadaczek; Yoji Yamashita; Hanna Mirek; Laszlo Tamas; Martha C Bohn; Charles Noble; John W Park; Krystof Bankiewicz
Journal:  Mol Ther       Date:  2006-05-02       Impact factor: 11.454

Review 5.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

6.  Over the barrier and through the blood: to CNS delivery we go.

Authors:  Kevin D Foust; Brian K Kaspar
Journal:  Cell Cycle       Date:  2009-12-05       Impact factor: 4.534

7.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

8.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

Authors:  Agnieszka Ciesielska; Piotr Hadaczek; Gabriele Mittermeyer; Shangzhen Zhou; J Fraser Wright; Krystof S Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

9.  Adeno-associated virus vectors can be efficiently produced without helper virus.

Authors:  T Matsushita; S Elliger; C Elliger; G Podsakoff; L Villarreal; G J Kurtzman; Y Iwaki; P Colosi
Journal:  Gene Ther       Date:  1998-07       Impact factor: 5.250

10.  Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10.

Authors:  Erin D Milligan; Evan M Sloane; Stephen J Langer; Pedro E Cruz; Marucia Chacur; Leah Spataro; Julie Wieseler-Frank; Sayamwong E Hammack; Steven F Maier; Terence R Flotte; John R Forsayeth; Leslie A Leinwand; Raymond Chavez; Linda R Watkins
Journal:  Mol Pain       Date:  2005-02-25       Impact factor: 3.395

View more
  74 in total

1.  Cerebellomedullary Cistern Delivery for AAV-Based Gene Therapy: A Technical Note for Nonhuman Primates.

Authors:  Lluis Samaranch; John Bringas; Philip Pivirotto; Waldy San Sebastian; John Forsayeth; Krystof Bankiewicz
Journal:  Hum Gene Ther Methods       Date:  2016-02       Impact factor: 2.396

2.  Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.

Authors:  Subha Karumuthil-Melethil; Michael S Marshall; Clifford Heindel; Benas Jakubauskas; Ernesto R Bongarzone; Steven J Gray
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.

Authors:  William A Liguore; Jacqueline S Domire; Dana Button; Yun Wang; Brett D Dufour; Sathya Srinivasan; Jodi L McBride
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

4.  Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats.

Authors:  J Hordeaux; L Dubreil; J Deniaud; F Iacobelli; S Moreau; M Ledevin; C Le Guiner; V Blouin; J Le Duff; A Mendes-Madeira; F Rolling; Y Cherel; P Moullier; M-A Colle
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

5.  Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies.

Authors:  John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2015-04       Impact factor: 11.454

6.  Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS.

Authors:  Jerusha Naidoo; Lisa M Stanek; Kousaku Ohno; Savanah Trewman; Lluis Samaranch; Piotr Hadaczek; Catherine O'Riordan; Jennifer Sullivan; Waldy San Sebastian; John R Bringas; Christopher Snieckus; Amin Mahmoodi; Amir Mahmoodi; John Forsayeth; Krystof S Bankiewicz; Lamya S Shihabuddin
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 7.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

Review 8.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

9.  Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.

Authors:  Subha Karumuthil-Melethil; Sahana Nagabhushan Kalburgi; Patrick Thompson; Michael Tropak; Michael D Kaytor; John G Keimel; Brian L Mark; Don Mahuran; Jagdeep S Walia; Steven J Gray
Journal:  Hum Gene Ther       Date:  2016-07       Impact factor: 5.695

10.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.

Authors:  Michael J Castle; Heikki T Turunen; Luk H Vandenberghe; John H Wolfe
Journal:  Methods Mol Biol       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.